Commercial immunoglobulin products now contain neutralising antibodies against SARS-CoV-2 spike antibody which are detectable in patient serum
Upasani, V.; O'Sullivan, M.; Moreira, F.; Workman, S.; Symes, A.; Burns, S. O.; Tadros, S.; McCoy, L. E.; Lowe, D. M.
Show abstract
Antibody-deficient patients respond poorly to COVID-19 vaccination and are at risk of severe or prolonged infection. Prophylaxis with anti-SARS-CoV-2 monoclonal antibodies has been considered. We here demonstrate that many immunoglobulin preparations now contain neutralising anti-SARS-CoV-2 antibodies which are transmitted to patients in good concentrations, albeit with significant differences between products.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD-20 therapy 93%
- Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany 92%
- Harnessing mRNA for the expression of monoclonal IgG and IgA in non-human primates. 92%
Similar papers in this journal
- IgG1 responses following SARS-CoV-2 infection are polyclonal and highly personalized, whereby each donor and each clone displays a distinct pattern of cross-reactivity against SARS-CoV-2 variants 92%
- High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge: a case for continued use of masks post-vaccination 90%
- Monoclonal antibody levels and protection from COVID-19 90%
Similar papers in this journal
- Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity 92%
- Characterising heterogeneity and sero-reversion in antibody responses to mild SARS⍰CoV-2 infection: a cohort study using time series analysis and mechanistic modelling 92%
- Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies 91%
Similar papers in this journal
- SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease 93%
- Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants 92%
- High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples 91%
Similar papers in this journal
- Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic 93%
- People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses 93%
- Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people living with HIV with hyporesponse after primary vaccination 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.